Autoantibody and IFN Burden Correlate With Nipocalimab Response in Sjögren's DiseaseByR. Hal Scofield, MDJune 10th 2026
Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and LupusByRihards Buss, MD,Jack Arnold, MBBS, MRCP, PhD,Lucy Carter, MBBS, PhDMay 5th 2026
From Rituximab to Ianalumab: The Evolution of Targeted Therapy in Sjögren DiseaseByVictoria JohnsonApril 30th 2026
Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next FrontierByRihards Buss, MD,Jack Arnold, MBBS, MRCP, PhDApril 22nd 2026
The Expanding Arsenal in Systemic Autoimmune Disease in 2025 and Beyond, With Orrin Troum, MD, and Alvin Wells, MD, PhDByOrrin M. Troum, MD,Alvin Wells, MD, PhDMarch 9th 2026